Dr Reddys Laboratories (RDY) Change in Intangibles (2009 - 2026)

Dr Reddys Laboratories (RDY) posted Change in Intangibles of $22.3 million for Q2 2026, up 500.88% on a QoQ basis from $3.7 million in Q2 2019.

Analysis

Dr Reddys Laboratories (RDY) Change in Intangibles (2009 - 2026) Analysis & Trends

Dr Reddys Laboratories has reported Change in Intangibles for 6 years, with the latest figure at $22.3 million in Q2 2026.

On a quarterly basis, Change in Intangibles changed N/A year-over-year to $22.3 million in Q2 2026; TTM through Jun 2026 was $22.3 million, a N/A change from a year earlier, with the FY2026 full-year figure at $15.0 million, up 66.67% from the prior year.
Change in Intangibles was $22.3 million for Q2 2026 at Dr Reddys Laboratories, up from $3.7 million in the prior quarter.
The five-year high for Change in Intangibles was $22.3 million in Q2 2026, with the low at $22.3 million in Q2 2026.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Change in Intangibles (Qtr)
1	Teva Pharmaceutical Industries	42.84 Bn	39.19 Bn	2.15 Bn	-
2	Viatris	19.13 Bn	18.24 Bn	1.46 Bn	-
3	Dr Reddys Laboratories	9.91 Bn	9.74 Bn	396.53 Mn	22.34 Mn
4	Amneal Pharmaceuticals	5.51 Bn	5.38 Bn	334.51 Mn	-
5	Bausch Health Companies	2.30 Bn	464.50 Mn	2.10 Bn	-
6	Alvotech	1.50 Bn	1.36 Bn	2.56 Mn	-16.90 Mn
7	Ani Pharmaceuticals	1.49 Bn	1.13 Bn	165.89 Mn	-
8	Amphastar Pharmaceuticals	1.00 Bn	714.13 Mn	93.47 Mn	-
9	Fennec Pharmaceuticals	402.10 Mn	360.85 Mn	17.15 Mn	-
10	RedHill Biopharma	178.35 Mn	178.35 Mn	-	-

Historic Data

Download Data